Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 13/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21965405 | 0.89 | CRBN (0.60) | CRBNDDB1 | |
| SCHEMBL26328134 | 0.85 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL26328143 | 0.78 | DDB1 (0.71) | CRBNDDB1 | |
| SCHEMBL26328216 | 0.76 | DDB1 (0.47) | CRBNDDB1 | |
| SCHEMBL26328213 | 0.76 | DDB1 (0.54) | CRBNDDB1 | |
| SCHEMBL26328146 | 0.76 | DDB1 (0.54) | CRBNDDB1 | |
| SCHEMBL26328198 | 0.76 | DDB1 (0.54) | CRBNDDB1 | |
| SCHEMBL26328152 | 0.76 | DDB1 (0.60) | CRBNDDB1 | |
| SCHEMBL26328186 | 0.74 | DDB1 (0.52) | CRBNDDB1 | |
| SCHEMBL26328235 | 0.74 | DDB1 (0.52) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | C4 THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279023-A1 | N/O-Linked Degrons and Degronimers for Protein Degradation | CRBN, CBL, STUB1 | CRBN 1/4885DDB1 319/4885CNR1 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.